M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

153

Enrollment

INDUSTRY

Sponsor class

Stopped Based on recommendations by an external Independent data Monitoring Committee (IDMC), Sponsor decided to discontinue this clinical study due to a low likelihood of achieving superiority in the efficacy endpoints versus standard of care.

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: M7824
DRUG: Placebo
DRUG: Durvalumab
DRUG: Etoposide
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Cisplatin
RADIATION: Intensity Modulated Radiation Therapy (IMRT)

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]